BenjaminMusherMD

Oncology • Houston, TX

Assistant Professor, Medicine, Baylor College of Medicine

Join to view full profile

Dr. Musher is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Musher's full profile

Already have an account?

Office
1504 Taub Loop
Houston, TX 77030
Phone+1 713-798-2500

Fax+1 713-798-1144

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2005 - 2008
University of WashingtonResidency, Internal Medicine, 2000 - 2003
Baylor College of MedicineClass of 2000

Certifications & Licensure

TX State Medical License 2009 - 2025
NC State Medical License 2017 - 2018
PA State Medical License 2004 - 2010
WA State Medical License 2003 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
Study of Metformin With Simvastatin for Men With Prostate Carcinoma Start of enrollment: 2012 Jan 01
Withdrawn
Phase 2
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Start of enrollment: 2013 May 01
Terminated
Phase 3
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting Start of enrollment: 2014 Feb 05
Completed
Phase 2
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer Start of enrollment: 2016 Nov 01
Recruiting
Phase 1, Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from ...
Benjamin L Musher, Eric K Rowinsky, Brandon G Smaglo, Wasif Abidi, Mohamed Othman
The Lancet. Oncology. 2024-04-01
38 citations
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).
Ethan Basch, Amylou C Dueck, Sandra A Mitchell, Harvey Mamon, Martin Weiser
Journal of Clinical Oncology. 2023-07-20
7 citations
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer.
Vivek Nimgaonkar, Viswesh Krishna, Vrishab Krishna, Ekin Tiu, Anirudh Joshi
Cell Reports. Medicine. 2023-04-18

Lectures

A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020

Press Mentions

Houston Cancer-Fighting Organization Launches Center to Support Early TrialsSeptember 3rd, 2024
Dan L Duncan Comprehensive Cancer Center Launches Phase 1 Clinical Trial ProgramAugust 19th, 2024
Rep. Joaquin Castro's Cancerous Tumors Are Rare but Manageable, Houston Experts SayFebruary 28th, 2023
Join now to see all